AbbVie schluckt AKTIONÄR-Hot-Stock Immunogen – Aktie schießt über 80 Prozent hoch
Der Pharma-Riese AbbVie will sein Onkologie-Business mit der Übernahme von Immunogen ausbauen und legt dafür satte 10,1 Milliarden Dollar auf…
171,170€
0,26%
Echtzeit-Aktienkurs Abbvie Inc.
Bid:
Ask:
Nachrichten zur Abbvie Inc. Aktie
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio By Reuters
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio…
: AbbVie $10.1 billion deal to buy ImmunoGen values the stock at a 95% premium
AbbVie Inc. ABBV announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN in a cash deal valued…
Biotech Stocks Rally After $10.1 Billion ImmunoGen Buyout
Big pharma’s $10.1 billion deal splash is giving biotech stocks a lift.
AbbVie, which sells widely-used drugs like Humira and Skyrizi,…
AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)
…
AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
Data from a mid-stage study on AbbVies (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain…
[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024
…
Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031
Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…
4 Large Drug Stocks to Watch as IBD Market Gains Traction
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players…
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
The FDA grants breakthrough therapy designation to AbbVies (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing…
: AbbVie says FDA has granted breakthrough therapy designation to epocritamab for a type of lymphoma
AbbVie Inc. ABBV said Monday the U.S. Food and Drug Administration has granted breakthrough therapy designation, or BTD, to its…
Rising Global Prevalence of Skin Diseases Drives the Antipruritics Market, Future Market Insights Predicts Expansion at a 4.2% CAGR through 2034
The growing geriatric population, rising burden of skin diseases, and rising R&D on novel biopharmaceuticals. AbbVie Inc., Allergan, Merck &…
Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%
The Global Glaucoma Treatment Market Size was valued at USD 6.4 Billion in 2022 and the Worldwide Glaucoma Treatment Market…
AbbVie suing Sandoz, four others to block generic Rinvoq: report
…
Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study
Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…
AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks
…
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
Both companies share prices have slipped recently.…
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? @themotleyfool #stocks $ABBV $PFE
Both companies share prices have slipped recently.…
AbbVie: Humira und die Sieben Zwerge - Aktienanalyse
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…
The Zacks Analyst Blog Highlights NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley
NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley are part of the Zacks top Analyst Blog.…
4 Large Drug Stocks Likely to Sail Through Industry Woes
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO),…
AbbVies $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock?
AbbVie is committed to rewarding shareholders, even during tough times.…
AbbVies $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock? @themotleyfool #stocks $ABBV
AbbVie is committed to rewarding shareholders, even during tough times.…
Top Research Reports for NVIDIA, Chevron & AbbVie
Todays Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie…
Aktienmarkt: Kurs der AbbVie-Aktie im Minus (127,3513 €)
Die AbbVie-Aktie notiert am Donnerstag leichter. Das Wertpapier notiert derzeit bei 136,22 US-Dollar. Für das Wertpapier von AbbVie steht gegenwärtig…
AbbVie, GSK, Teva cited as FTC tackles improper Orange Book patents
…
US FTC disputes listing for more than 100 patents in FDA Orange Book
The U.S. Federal Trade Commission (FTC) on Tuesday said it sent notice letters to Abbvie , AstraZeneca , Teva and…
Analyst Report: AbbVie Inc
…
Pfizers Coming for AbbVies Market Share. Heres What It Means for Investors @themotleyfool #stocks $PFE $ABBV
AbbVie has a head start, but that might not be enough to save its top line.…
Pfizers Coming for AbbVies Market Share. Heres What It Means for Investors
AbbVie has a head start, but that might not be enough to save its top line.…
Global Botulinum Toxin Market Outlook 2023-2030: Key Players such as AbbVie and Merz Pharma Leading the Competition
Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The "Botulinum Toxin - Global Strategic Business Report" report has been…
Is AbbVie Still a Good Dividend Stock to Buy?
The decline in sales of Humira, AbbVies top seller, is enough to make anyone nervous.…
Is AbbVie Still a Good Dividend Stock to Buy? @themotleyfool #stocks $ABBV
The decline in sales of Humira, AbbVies top seller, is enough to make anyone nervous.…
5 Solid Stocks to Watch That Recently Hiked Dividends
AbbVie Inc. (ABBV), Exxon Mobil Corporation (XOM), Kontoor Brands, Inc. (KTB), Select Water Solutions, Inc. (WTTR) and Macatawa Bank Corporation…
AbbVie shares rise after Barclays upgrades rating of U.S. drugmaker By Investing.com
AbbVie shares rise after Barclays upgrades rating of U.S. drugmaker…
NEXGEL announces supply agreement with AbbVie
NEXGEL (NASDAQ:NXGL) announced that its CG Converting and Packaging subsidiary has executed a supply agreement with biopharmaceutical giant AbbVie Inc to be...…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…